Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply

Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.

Inflammatory bowel diseases·2026

Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression.

Journal of Crohn's & colitis·2026

Classifications of rheumatological extraintestinal manifestations in inflammatory bowel disease: Unmet needs in clinical practice and trials.

Inflammatory bowel diseases·2026

Patients with Crohn's disease achieving transmural healing experience superior long-term outcomes compared with those with endoscopic or radiologic healing alone.

Inflammatory bowel diseases·2026

Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy.

Journal of Crohn's & colitis·2026

The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials.

Journal of Crohn's & colitis·2026

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta.

Alimentary pharmacology & therapeutics·2026

Clinical Trial: Randomised Placebo-Controlled Trial of Methylcellulose and Psyllium Gels on Inulin-Induced Colonic Gas.

Alimentary pharmacology & therapeutics·2026

HLA-A*11:01 Identifies Patients at Risk for Persistent Viraemia and Advanced Fibrosis in HDV Infection.

Alimentary pharmacology & therapeutics·2026

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Alimentary pharmacology & therapeutics·2026

Risk of Coeliac Disease After Immune Checkpoint Inhibitor Exposure in Patients With Cancer.

Alimentary pharmacology & therapeutics·2026

Pharmacokinetic and Pharmacodynamic Variability Predict Late Events After Paediatric Liver Transplantation: Derivation and External Validation of a Landmark Risk Score.

Alimentary pharmacology & therapeutics·2026

Outcome-Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry.

Journal of the American Heart Association·2026

Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.

Cancer discovery·2026

Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series.

Gastro hep advances·2026

Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis.

Kidney international reports·2026

Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.

Frontiers in pharmacology·2026

FcRn Inhibition in Autoantibody-Mediated Autoimmune Diseases: From Broad Immunosuppression to Precision IgG Modulation.

Mediterranean journal of rheumatology·2026

Related Experiment Videos

Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply

Related Concept Videos

Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.

Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression.

Classifications of rheumatological extraintestinal manifestations in inflammatory bowel disease: Unmet needs in clinical practice and trials.

Patients with Crohn's disease achieving transmural healing experience superior long-term outcomes compared with those with endoscopic or radiologic healing alone.

Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy.

The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials.

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta.

Clinical Trial: Randomised Placebo-Controlled Trial of Methylcellulose and Psyllium Gels on Inulin-Induced Colonic Gas.

HLA-A*11:01 Identifies Patients at Risk for Persistent Viraemia and Advanced Fibrosis in HDV Infection.

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Risk of Coeliac Disease After Immune Checkpoint Inhibitor Exposure in Patients With Cancer.

Pharmacokinetic and Pharmacodynamic Variability Predict Late Events After Paediatric Liver Transplantation: Derivation and External Validation of a Landmark Risk Score.

Outcome-Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry.

Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.

Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series.

Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis.

Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.

FcRn Inhibition in Autoantibody-Mediated Autoimmune Diseases: From Broad Immunosuppression to Precision IgG Modulation.

Related Experiment Videos

Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply

Related Concept Videos

Related Articles